Amdray

Valspodar (PSC833) is an experimental cancer treatment and chemosensitizer.[1] It is a derivative of ciclosporin D (cyclosporin D). Its primary use is as an inhibitor of the efflux transporter P-glycoprotein. Previous studies in animal models have found it to be effective at preventing cancer cell resistance to chemotherapeutics, but these findings did not translate to clinical success.[2] Adverse effects Valspodar can cause nerve damage.[1]... [wikipedia]